Approval is the beginning of the European commercial question, not the end of it. The EU HTA Regulation has required a Joint Clinical Assessment for new oncology medicines and advanced therapies since January 2025, harmonizing the clinical dossier while leaving price to each Member State; Germany ties relief from its pricing guardrails to where a company runs its research; Switzerland's three-year review repriced hundreds of products in 2025; digital therapeutics in Germany are now paid in part on measured outcomes; and the EU Pharma Package attaches an exclusivity cost to a selective launch. The analyses below read those mechanisms from the US originator's side, where the comparator fixed at trial design, the location of a study and the sequence of launches have become pricing terms.
5 insights · latest June 2026
Switzerland's 2025 three-year pricing review repriced over 300 pharma products. Cascade effects on R&D investment, cantonal incentives, and market access.
The EU HTA Regulation has required a Joint Clinical Assessment for new oncology medicines and ATMPs since 12 January 2025; it harmonizes the clinical dossier, not national pricing, and its PICO comparators are fixed at trial design.
Germany's Medizinforschungsgesetz has, since 1 January 2025, tied relief from the AMNOG pricing guardrails and the option of a confidential reimbursement amount, bought with a nine percent discount, to where a company runs its trials and research.
Germany's Digital-Gesetz rewrote § 134 SGB V so that from 2026 at least 20 percent of a DiGA's negotiated price turns on measured outcomes, and the BfArM directory now admits Class IIb software on stricter evidence terms.
EU Pharma Package Article 56a lets a Member State demand a launch; non-compliance can strip regulatory market protection in that territory. For US originators, selective EU launch strategy now carries a direct exclusivity cost.
Counsel on this topic: Swiss market access & reimbursement counsel.
Good questions deserve specific answers.
Get in Touch